Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis?
| Autor: | Sierra L Barnes, Christopher H. Domen, Thomas R. Wodushek, Brian D. Hoyt, Michael R. Greher, Patrick Hosokawa |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
050103 clinical psychology
medicine.medical_specialty Multiple Sclerosis Objective data Sample (statistics) Test validity Neuropsychological Tests Sensitivity and Specificity 03 medical and health sciences 0302 clinical medicine Physical medicine and rehabilitation medicine Advanced disease Humans 0501 psychology and cognitive sciences Retrospective Studies business.industry Multiple sclerosis 05 social sciences Reproducibility of Results Cognition Retrospective cohort study General Medicine medicine.disease Psychiatry and Mental health Clinical Psychology Neuropsychology and Physiological Psychology Relapsing remitting business 030217 neurology & neurosurgery |
| Zdroj: | Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists. 35(5) |
| ISSN: | 1873-5843 |
| Popis: | Objective Data for the use of embedded performance validity tests (ePVTs) with multiple sclerosis (MS) patients are limited. The purpose of the current study was to determine whether ePVTs previously validated in other neurological samples perform similarly in an MS sample. Methods In this retrospective study, the prevalence of below-criterion responding at different cut-off scores was calculated for each ePVT of interest among patients with MS who passed a stand-alone PVT. Results Previously established PVT cut-offs generally demonstrated acceptable specificity when applied to our sample. However, the overall cognitive burden of the sample was limited relative to that observed in prior large-scale MS studies. Conclusion The current study provides initial data regarding the performance of select ePVTs among an MS sample. Results indicate most previously validated cut-offs avoid excessive false positive errors in a predominantly relapsing remitting MS sample. Further validation among MS patients with more advanced disease is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|